Novartis CEO Vas Narasimhan last month said the company’s Advair generic—specifically its approval this year—was one of his top three worries for 2018. That worry just grew. In a blow to Novartis and a boon for GlaxoSmithKline, the FDA rejected the generic.Original Article
Bad news for Novartis, good for GlaxoSmithKline: Sandoz’ Advair copy stiff-armed at FDA
